BRPI0616264B8 - composto 7-[2-[4-(6-flúor-3-metil-1,2-benzissoxazol-5- il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c]-pirimidin-5-amina, e, composição farmacêutica - Google Patents
composto 7-[2-[4-(6-flúor-3-metil-1,2-benzissoxazol-5- il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c]-pirimidin-5-amina, e, composição farmacêuticaInfo
- Publication number
- BRPI0616264B8 BRPI0616264B8 BRPI0616264A BRPI0616264A BRPI0616264B8 BR PI0616264 B8 BRPI0616264 B8 BR PI0616264B8 BR PI0616264 A BRPI0616264 A BR PI0616264A BR PI0616264 A BRPI0616264 A BR PI0616264A BR PI0616264 B8 BRPI0616264 B8 BR PI0616264B8
- Authority
- BR
- Brazil
- Prior art keywords
- benzisoxazol
- triazol
- pyrazol
- pyrimidin
- propynyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000027776 Extrapyramidal disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000005793 Restless legs syndrome Diseases 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72002705P | 2005-09-23 | 2005-09-23 | |
US60/720,027 | 2005-09-23 | ||
PCT/US2006/037003 WO2007038284A1 (en) | 2005-09-23 | 2006-09-21 | 7-[2-[4-(6-FLUORO-3-METHYL-1,2-BENZISOXAZOL-5-YL)-1-PIPERAZINYL]ETHYL]-2-(1-PROPYNYL)-7H-PYRAZOLO-[4,3-e]-[1,2,4]-TRIAZOLO-[1,5-c]-PYRIMIDIN-5 AMINE |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0616264A2 BRPI0616264A2 (pt) | 2011-06-14 |
BRPI0616264B1 BRPI0616264B1 (pt) | 2020-12-22 |
BRPI0616264B8 true BRPI0616264B8 (pt) | 2021-05-25 |
Family
ID=37487759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0616264A BRPI0616264B8 (pt) | 2005-09-23 | 2006-09-21 | composto 7-[2-[4-(6-flúor-3-metil-1,2-benzissoxazol-5- il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c]-pirimidin-5-amina, e, composição farmacêutica |
Country Status (31)
Country | Link |
---|---|
US (2) | US7572802B2 (pt) |
EP (1) | EP1937687B1 (pt) |
JP (1) | JP4808779B2 (pt) |
KR (1) | KR101396614B1 (pt) |
CN (2) | CN102716131B (pt) |
AR (1) | AR056080A1 (pt) |
AT (1) | ATE503759T1 (pt) |
AU (1) | AU2006294633B8 (pt) |
BR (1) | BRPI0616264B8 (pt) |
CA (1) | CA2623047C (pt) |
CY (1) | CY1111921T1 (pt) |
DE (1) | DE602006021042D1 (pt) |
DK (1) | DK1937687T3 (pt) |
EC (1) | ECSP088297A (pt) |
ES (1) | ES2361856T3 (pt) |
HK (1) | HK1119681A1 (pt) |
HR (1) | HRP20110466T1 (pt) |
IL (1) | IL190275A (pt) |
MY (1) | MY146429A (pt) |
NO (1) | NO341760B1 (pt) |
NZ (1) | NZ566737A (pt) |
PE (1) | PE20070521A1 (pt) |
PL (1) | PL1937687T3 (pt) |
PT (1) | PT1937687E (pt) |
RS (1) | RS51702B (pt) |
RU (1) | RU2417997C2 (pt) |
SG (1) | SG165419A1 (pt) |
SI (1) | SI1937687T1 (pt) |
TW (1) | TWI335329B (pt) |
WO (1) | WO2007038284A1 (pt) |
ZA (1) | ZA200802550B (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ527142A (en) | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
US7691869B2 (en) | 2007-03-30 | 2010-04-06 | King Pharmaceuticals Research And Development, Inc. | Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity |
US8859566B2 (en) | 2009-03-13 | 2014-10-14 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds |
US8598343B2 (en) | 2009-08-07 | 2013-12-03 | Merck Sharp & Dohme Corp. | Process for preparing a 2-alkynyl substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine |
WO2011101861A1 (en) | 2010-01-29 | 2011-08-25 | Msn Laboratories Limited | Process for preparation of dpp-iv inhibitors |
CA2812378C (en) * | 2010-09-24 | 2016-11-29 | Advinus Therapeutics Limited | Fused tricyclic compounds as adenosine receptor antagonist |
WO2012135083A1 (en) * | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | METABOLITES OF 7-(2-(4-(6-FLUORO-3-METHYLBENZO[d]ISOXAZOL-5-YL)PIPERAZIN-1-YL)ETHYL)-2-(PROP-1-YNYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
WO2014101113A1 (en) * | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
WO2014101120A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
WO2014128882A1 (ja) * | 2013-02-21 | 2014-08-28 | 医療法人 和楽会 | 不安うつ病の治療薬 |
WO2015027431A1 (en) | 2013-08-29 | 2015-03-05 | Merck Sharp & Dohme Corp. | 2,2-difluorodioxolo a2a receptor antagonists |
CN111943890B (zh) | 2014-11-03 | 2023-10-31 | 艾欧米制药有限公司 | 药用化合物 |
WO2016089796A1 (en) * | 2014-12-04 | 2016-06-09 | Merck Sharp & Dohme Corp. | Formulation inhibiting effects of low acid environment |
CN106543095B (zh) * | 2016-09-23 | 2019-03-05 | 江苏大学 | 一种基于2-羟基苯乙酮肟及其衍生物一锅制备苯并异噁唑的方法 |
WO2019118313A1 (en) | 2017-12-13 | 2019-06-20 | Merck Sharp & Dohme Corp. | Imidazo [1,2-c] quinazolin-5-amine compounds with a2a antagonist properties |
CN110742893B (zh) * | 2018-07-23 | 2024-04-05 | 百济神州(北京)生物科技有限公司 | A2a受体拮抗剂治疗癌症的方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE462170B (sv) | 1987-10-27 | 1990-05-14 | Aahlstrom Corp | Avlaegsnande av loesta och kolloidala makromolekylaera organiska aemnen ur effluenter |
IT1264901B1 (it) | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
ATE208199T1 (de) * | 1993-07-27 | 2001-11-15 | Kyowa Hakko Kogyo Kk | Arzneimittel gegen parkinsonsche krankheit |
IT1275420B (it) | 1995-06-02 | 1997-08-05 | Schering Plough S P A | Metodo per misurare l'affinita' di legame al recettore a2a dell'adenosina di componenti di interesse farmacologico mediante l'uso del ligando triziato (3h)-sch 58261 |
IT1277392B1 (it) | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
KR100520907B1 (ko) | 2000-05-26 | 2005-10-11 | 쉐링 코포레이션 | 아데노신 A2a수용체 길항제 |
GB0100624D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
KR100687954B1 (ko) | 2001-10-15 | 2007-02-27 | 쉐링 코포레이션 | 아데노신 A2a 수용체 길항제로서의이미다조(4,3-e)-1,2,4-트리아졸로(1,5-c) 피리미딘 |
US7414058B2 (en) | 2002-12-19 | 2008-08-19 | Schering Corporation | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
BRPI0409787B8 (pt) * | 2003-04-23 | 2021-05-25 | Merck Sharp & Dohme | antagonistas receptores da 2-alquinil- e 2-alquenil-pirazol-[4,3-e]-1,2,4-triazol-[1,5-c]-pirimidina adenosina a2a |
ES2342082T3 (es) | 2004-04-21 | 2010-07-01 | Schering Corporation | Antagonistas de receptores a2a de adenosina de pirazolo(4,3-e)-1,2,4-triazolo(1,5-c)pirimidina. |
-
2006
- 2006-09-20 AR ARP060104110A patent/AR056080A1/es active IP Right Grant
- 2006-09-20 PE PE2006001140A patent/PE20070521A1/es active IP Right Grant
- 2006-09-21 US US11/525,065 patent/US7572802B2/en active Active
- 2006-09-21 CN CN201110394181.7A patent/CN102716131B/zh not_active Expired - Fee Related
- 2006-09-21 SG SG201006970-6A patent/SG165419A1/en unknown
- 2006-09-21 PL PL06804036T patent/PL1937687T3/pl unknown
- 2006-09-21 WO PCT/US2006/037003 patent/WO2007038284A1/en active Application Filing
- 2006-09-21 CN CN2006800352004A patent/CN101273045B/zh not_active Expired - Fee Related
- 2006-09-21 RS RS20110262A patent/RS51702B/en unknown
- 2006-09-21 PT PT06804036T patent/PT1937687E/pt unknown
- 2006-09-21 ES ES06804036T patent/ES2361856T3/es active Active
- 2006-09-21 NZ NZ566737A patent/NZ566737A/en not_active IP Right Cessation
- 2006-09-21 JP JP2008532422A patent/JP4808779B2/ja not_active Expired - Fee Related
- 2006-09-21 AU AU2006294633A patent/AU2006294633B8/en not_active Ceased
- 2006-09-21 MY MYPI20080750A patent/MY146429A/en unknown
- 2006-09-21 SI SI200631017T patent/SI1937687T1/sl unknown
- 2006-09-21 DE DE602006021042T patent/DE602006021042D1/de active Active
- 2006-09-21 BR BRPI0616264A patent/BRPI0616264B8/pt not_active IP Right Cessation
- 2006-09-21 KR KR1020087007052A patent/KR101396614B1/ko active IP Right Grant
- 2006-09-21 AT AT06804036T patent/ATE503759T1/de active
- 2006-09-21 CA CA2623047A patent/CA2623047C/en not_active Expired - Fee Related
- 2006-09-21 DK DK06804036.9T patent/DK1937687T3/da active
- 2006-09-21 EP EP06804036A patent/EP1937687B1/en active Active
- 2006-09-21 RU RU2008115239/04A patent/RU2417997C2/ru active
- 2006-09-21 TW TW095134895A patent/TWI335329B/zh not_active IP Right Cessation
-
2008
- 2008-03-18 IL IL190275A patent/IL190275A/en active IP Right Grant
- 2008-03-19 ZA ZA200802550A patent/ZA200802550B/xx unknown
- 2008-03-19 EC EC2008008297A patent/ECSP088297A/es unknown
- 2008-04-22 NO NO20081924A patent/NO341760B1/no not_active IP Right Cessation
- 2008-10-24 HK HK08111733.1A patent/HK1119681A1/xx not_active IP Right Cessation
-
2009
- 2009-07-06 US US12/498,013 patent/US8389532B2/en active Active
-
2011
- 2011-06-20 HR HR20110466T patent/HRP20110466T1/hr unknown
- 2011-06-28 CY CY20111100618T patent/CY1111921T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0616264B8 (pt) | composto 7-[2-[4-(6-flúor-3-metil-1,2-benzissoxazol-5- il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c]-pirimidin-5-amina, e, composição farmacêutica | |
BRPI0511967A (pt) | usos de derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetrahidro-2h-pirido[2,3-d] pirimidina e compostos relacionados para o tratamento de cáncer, suas composições farmacêuticas, embalagens comerciais e respectivo kit | |
ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
BR112015023412A8 (pt) | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante, sua composição farmacêutica e seu uso. | |
BR112014007310A2 (pt) | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante | |
ECSP088973A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
BRPI0924183B8 (pt) | inibidores de cdk4/6 quinase, seus usos e sua forma cristalina iii, e formulação farmacêutica | |
CL2010001348A1 (es) | Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad. | |
BRPI0515446A (pt) | amidas bicìclicas como inibidores de cinases | |
SV2011003939A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
BRPI0820112B8 (pt) | derivados de isoxazol-piridina, seu uso e processos de preparação e medicamento | |
BRPI0514230A (pt) | compostos de amido e seu uso como produtos farmacêuticos | |
CL2009000035A1 (es) | Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras. | |
BRPI0507966A (pt) | uso de meloxicam para o tratamento de doenças respiratórias em porcos | |
UY28945A1 (es) | Derivados de pirrolopiridina | |
DE602006004844D1 (de) | Pyrrolopyrimidine verwendbar als protein kinase inhibitoren | |
ECSP099387A (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis | |
BRPI0517458A (pt) | derivados da xantina com atividade para o receptor hm74a | |
BRPI0611863A2 (pt) | composto, bem como composiÇço e kit compreendendo o mesmo, composto intermediÁrio na preparaÇço do mesmo, mÉtodo para tratamento e uso do mesmo | |
BRPI0814299B8 (pt) | preparação sólida compreendendo alogliptina e cloridreto de metformina, uso de uma preparação sólida, e, métodos para estabilizar um composto em uma preparação sólida, e para produzir uma preparação sólida | |
BR112014011850A8 (pt) | Derivados de aminopirimidina, seus usos, e composição farmacêutica | |
CR6726A (es) | Compuestos azapoliciclicos condensados con arilo | |
EA200971107A1 (ru) | Катехоламиновые производные, полезные для лечения болезни паркинсона | |
BR112015019754A8 (pt) | derivados de 2-((4-amino-3-(3-fluoro-5-hidroxifenil)-1h-pirazolo[3,4-d]pirimidin-1-il)metil)-3-(2-(trifluoro-metil)bezil)quinazolin-4(3h)-ona e seu uso como inibidores de fosfoinositídeo 3-quinase | |
SV2008002958A (es) | Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania referencia cruzada ref. prd2592sv |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
B25G | Requested change of headquarter approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/12/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/09/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 17A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2741 DE 18-07-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |